# AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

> **NCT00243061** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Acral Lentiginous Malignant Melanoma
- Ciliary Body and Choroid Melanoma, Medium/Large Size
- Ciliary Body and Choroid Melanoma, Small Size
- Extraocular Extension Melanoma
- Intraocular Melanoma
- Iris Melanoma
- Lentigo Maligna Malignant Melanoma
- Recurrent Melanoma
- Stage, Intraocular Melanoma
- Stage IV Melanoma
- Superficial Spreading Malignant Melanoma

## Interventions

- **DRUG:** cediranib maleate

## Key facts

- **NCT ID:** NCT00243061
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00243061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00243061, "AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00243061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*